Sanofi receives Investment Bank Analyst Rating Update
By John Kruzel WASHINGTON (Reuters) -The U.S. Supreme Court on Thursday ruled against Amgen Inc (NASDAQ:AMGN) in its bid to revive patents on its cholesterol-lowering drug...
refractory AML, and for UCART20x22 in the NatHaLi-01 clinical trial….
Traders await US economic data to justify strongest monthly stock advance in 3 decades Oil rebound slows Bitcoin close to all-time high Key EventsThe most powerful global, monthly...
European equities opened firmer again on Thursday morning, extending gains from a very strong session on Wall Street. France’s CAC led the way after President Macron announced an...
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
|Average||110.490 (+16.330% Upside)|
|No. of Analysts||21|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Strong Sell||Strong Buy|
|Summary||Strong Buy||Strong Buy||Buy||Strong Sell||Strong Buy|